Oruka Therapeutics annual debt-to-assets ratio
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Oruka Therapeutics Debt-to-Assets Ratio Growth & History (ORKA)
Oruka Therapeutics's debt-to-assets ratio was 0.00 for fiscal 2025.
View full Oruka Therapeutics company overviewOruka Therapeutics annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.00 | 0.00 | +61.76% |
| 2024 | 2024-12-31 | 0.00 | −0.00 | −66.95% |
| 2023 | 2023-12-31 | 0.01 | −0.00 | −16.81% |
| 2022 | 2022-12-31 | 0.01 | 0.00 | +1.09% |
| 2021 | 2021-12-31 | 0.01 | −0.00 | −1.45% |
| 2020 | 2020-12-31 | 0.01 | 0.01 | — |
| 2019 | 2019-12-31 | 0.00 | 0.00 | — |
| 2018 | 2018-12-31 | 0.00 | 0.00 | — |
| 2017 | 2017-12-31 | 0.00 | 0.00 | — |
| 2016 | 2016-12-31 | 0.00 | 0.00 | — |
| 2015 | 2015-12-31 | 0.00 | — | — |
Oruka Therapeutics quarterly debt-to-assets ratio
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.00 | −0.00 | −65.66% |
| Q1 2026 | 2026-03-31 | 0.00 | 0.00 | +42.64% |
| Q4 2025 | 2025-12-31 | 0.00 | 0.00 | +61.76% |
| Q3 2025 | 2025-09-30 | 0.00 | 0.00 | +57.36% |
| Q2 2025 | 2025-06-30 | 0.01 | 0.01 | +817.71% |
| Q1 2025 | 2025-03-31 | 0.00 | 0.00 | +92.03% |
| Q4 2024 | 2024-12-31 | 0.00 | −0.00 | −66.95% |
| Q3 2024 | 2024-09-30 | 0.00 | −0.01 | −68.94% |
| Q2 2024 | 2024-06-30 | 0.00 | −0.01 | −91.14% |
| Q1 2024 | 2024-03-31 | 0.00 | −0.01 | −84.59% |
| Q4 2023 | 2023-12-31 | 0.01 | −0.00 | −16.81% |
| Q3 2023 | 2023-09-30 | 0.01 | −0.00 | −15.55% |
| Q2 2023 | 2023-06-30 | 0.01 | −0.00 | −11.45% |
| Q1 2023 | 2023-03-31 | 0.01 | −0.00 | −5.87% |
| Q4 2022 | 2022-12-31 | 0.01 | 0.00 | +1.09% |
| Q3 2022 | 2022-09-30 | 0.01 | 0.00 | +7.99% |
| Q2 2022 | 2022-06-30 | 0.01 | 0.00 | +13.20% |
| Q1 2022 | 2022-03-31 | 0.01 | 0.00 | +38.63% |
| Q4 2021 | 2021-12-31 | 0.01 | −0.00 | −1.45% |
| Q3 2021 | 2021-09-30 | 0.01 | 0.01 | — |
| Q2 2021 | 2021-06-30 | 0.01 | 0.01 | — |
| Q1 2021 | 2021-03-31 | 0.01 | 0.01 | — |
| Q4 2020 | 2020-12-31 | 0.01 | 0.01 | — |
| Q3 2020 | 2020-09-30 | 0.00 | 0.00 | — |
| Q2 2020 | 2020-06-30 | 0.00 | 0.00 | — |
| Q1 2020 | 2020-03-31 | 0.00 | 0.00 | — |
| Q4 2019 | 2019-12-31 | 0.00 | 0.00 | — |
| Q3 2019 | 2019-09-30 | 0.00 | 0.00 | — |
| Q2 2019 | 2019-06-30 | 0.00 | 0.00 | — |
| Q1 2019 | 2019-03-31 | 0.00 | 0.00 | — |
| Q4 2018 | 2018-12-31 | 0.00 | 0.00 | — |
| Q3 2018 | 2018-09-30 | 0.00 | 0.00 | — |
| Q2 2018 | 2018-06-30 | 0.00 | 0.00 | — |
| Q1 2018 | 2018-03-31 | 0.00 | 0.00 | — |
| Q4 2017 | 2017-12-31 | 0.00 | 0.00 | — |
| Q3 2017 | 2017-09-30 | 0.00 | 0.00 | — |
| Q2 2017 | 2017-06-30 | 0.00 | 0.00 | — |
| Q1 2017 | 2017-03-31 | 0.00 | 0.00 | — |
| Q4 2016 | 2016-12-31 | 0.00 | 0.00 | — |
| Q3 2016 | 2016-09-30 | 0.00 | — | — |
| Q2 2016 | 2016-06-30 | 0.00 | — | — |
| Q1 2016 | 2016-03-31 | 0.00 | — | — |
| Q4 2015 | 2015-12-31 | 0.00 | — | — |
Oruka Therapeutics debt-to-assets ratio trends
Over the last five fiscal years, Oruka Therapeutics's debt-to-assets ratio decreased from 0.01 to 0.00, a change of −0.00. The latest reported quarter, Q2 2026, shows 0.00.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oruka Therapeutics source filings ↗Community posts
Oruka’s psoriasis study supports planned Phase 3 trials after strong skin clearance
Oruka ($ORKA) reported positive 16-week results for ORKA-001 in the randomized Phase 2b EVERLAST-B psoriasis study. Among 46 patients assigned the highest dose, 61% achieved complete skin clearance, compared with none of 47 placebo recipien ...
